Modalis Therapeutics Corporation Logo

Modalis Therapeutics Corporation

Develops epigenome editing therapies for genetic muscular, heart, and CNS disorders.

4883 | T

Overview

Corporate Details

ISIN(s):
JP3922600006
LEI:
Country:
Japan
Address:
中央区日本橋本町三丁目11番5号
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

Modalis Therapeutics Corporation is a biotechnology company that pioneers the development of therapeutics for genetic diseases through epigenome editing. The company's proprietary core platform, CRISPR-GNDM®, is an advanced technology designed to regulate gene expression by selectively activating or suppressing specific genes without altering the underlying DNA sequence. This system utilizes a compact editor that can be delivered to target cells via AAV vectors. Modalis operates a hybrid business model, advancing therapeutic candidates through both in-house development pipelines for subsequent licensing and collaborative partnerships. Its development pipeline is focused on addressing unmet medical needs in muscular disorders, cardiomyopathy, and central nervous system (CNS) disorders.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-14 08:48
Registration Form
訂正有価証券届出書(組込方式)
Japanese 237.5 KB
2025-08-14 08:31
Regulatory News Service
確認書
Japanese 8.9 KB
2025-08-14 08:30
Interim Report
半期報告書-第10期(2025/01/01-2025/12/31)
Japanese 266.6 KB
2025-08-07 08:32
Registration Form
有価証券届出書(組込方式)
Japanese 334.6 KB
2025-03-28 07:52
Post-Annual General Meeting Information
臨時報告書
Japanese 28.4 KB
2025-03-27 08:32
Governance Information
内部統制報告書-第9期(2024/01/01-2024/12/31)
Japanese 24.1 KB
2025-03-27 08:30
Registration Form
確認書
Japanese 8.7 KB
2025-03-27 08:29
Annual Report
有価証券報告書-第9期(2024/01/01-2024/12/31)
Japanese 2.1 MB
2025-02-21 07:31
Audit Report / Information
臨時報告書
Japanese 21.5 KB
2024-08-13 08:14
Registration Form
訂正有価証券届出書(組込方式)
Japanese 293.9 KB
2024-08-13 07:58
Interim Report
半期報告書-第9期(2024/01/01-2024/12/31)
Japanese 249.6 KB
2024-08-13 07:58
Registration Form
確認書
Japanese 8.9 KB
2024-08-07 08:01
Registration Form
有価証券届出書(組込方式)
Japanese 495.2 KB
2024-05-14 06:00
Quarterly Report
四半期報告書-第9期第1四半期(2024/01/01-2024/03/31)
Japanese 166.1 KB
2024-05-14 06:00
Report Publication Announcement
確認書
Japanese 8.9 KB

Automate Your Workflow. Get a real-time feed of all Modalis Therapeutics Corporation filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Modalis Therapeutics Corporation

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Modalis Therapeutics Corporation via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

InterDigital, Inc. Logo
Develops and licenses essential wireless, video, and AI technologies for mobile devices and networks.
United States of America
IDCC
Interworks Confidence Inc. Logo
Specialized staffing and recruitment for the game, entertainment, and manufacturing sectors.
Japan
7374
INTLOOP Inc. Logo
Offers consulting, tech, and HR solutions leveraging a vast freelance professional network.
Japan
9556
IntoCell, Inc. Logo
Develops and licenses proprietary ADC platform technologies for cancer & immune therapies.
South Korea
287840
Intracom S.A. Holdings Logo
A multinational group delivering IT solutions, defense electronics, and construction projects.
Greece
INTRK
Inventionmed Spolka Akcyjna Logo
Develops VR medical simulators with haptic feedback for dermatology training.
Poland
INM
Inventiva Logo
Clinical-stage biopharma developing oral therapies for fibrosis, oncology, & lysosomal disorders.
France
IVA
A CRO advancing precision medicine via genomic analysis and clinical trial support services.
South Korea
216400
IQVIA HOLDINGS INC. Logo
Global provider of analytics, tech, and clinical research for life sciences and healthcare.
United States of America
IQV
Isofol Medical Logo
Developing a drug to enhance chemotherapy efficacy for solid tumors like colorectal cancer.
Sweden
ISOFOL

Talk to a Data Expert

Have a question? We'll get back to you promptly.